Exagen (XGN) Competitors

Exagen (NASDAQ:XGN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.

Do insiders and institutionals hold more shares of XGN or PSNL?

75.3% of Exagen shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 26.1% of Exagen shares are held by company insiders. Comparatively, 3.8% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is XGN or PSNL more profitable?

Exagen has a net margin of -30.36% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-30.36%	-92.58%	-33.74%
Personalis	-104.52%	-66.07%	-41.34%

Does the MarketBeat Community favor XGN or PSNL?

Personalis received 101 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 68.31% of users gave Personalis an outperform vote while only 58.54% of users gave Exagen an outperform vote.

Company	Underperform	Outperform
Exagen	Outperform Votes 24 58.54%	Underperform Votes 17 41.46%
Personalis	Outperform Votes 125 68.31%	Underperform Votes 58 31.69%

Does the media prefer XGN or PSNL?

In the previous week, Exagen had 1 more articles in the media than Personalis. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Personalis. Exagen's average media sentiment score of 0.47 beat Personalis' score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings and valuation, XGN or PSNL?

Exagen has higher earnings, but lower revenue than Personalis. Exagen is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$55.64M	1.44	-$23.69M	-$0.83	-5.41
Personalis	$84.61M	3.33	-$108.30M	-$1.37	-2.33

Do analysts prefer XGN or PSNL?

Exagen currently has a consensus target price of $7.50, suggesting a potential upside of 67.04%. Personalis has a consensus target price of $7.80, suggesting a potential upside of 144.51%. Given Personalis' higher possible upside, analysts plainly believe Personalis is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Personalis	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, XGN or PSNL?

Exagen has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Summary

Personalis beats Exagen on 9 of the 17 factors compared between the two stocks.